SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Sugar Ray Robinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSugar Ray Robinson
Date of birth1921-05-03
IdentifiersMRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318
Document date1984-08-18
AuthorLangston Pryce-Okonjo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review: amyloid PET result and the diagnosis. [S]

History of Present Illness

Sugar Ray Robinson returns six weeks after intake with his care partner, whom he asked to be present. The amyloid PET two weeks ago was positive. He was asked first how much he wanted to know and said he wanted it straight. The diagnosis of Alzheimer's disease at the stage of mild dementia was explained with the PET, MRI and test results, in plain words and in writing. He was quiet, then asked whether boxing had caused it; that question was answered honestly. His home glucose readings ran 95 to 150 mg/dL, with one reading of 68 mg/dL before lunch on glipizide. He has not driven. His care partner finds the evenings and the repeated questions tiring. [S]

ElementDetail
Amyloid PETPositive, widespread cortical uptake
DiagnosisMild dementia due to Alzheimer's disease, early onset
Home glucose95 to 150 mg/dL; one reading of 68 mg/dL on glipizide
ECGSinus rhythm 70, normal intervals
Care partnerZarit Burden Interview 18 (mild), narrative

Review of Systems

SystemResultFinding
NeurologicalPositiveMemory loss unchanged; no falls
PsychiatricNegativeSad at the news but not depressed; no thoughts of self-harm
EndocrinePositiveOne low glucose reading before lunch, with sweating

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route1982-03-01activeS
Glipizide 5 mg oral tablet, one tablet before breakfastOne tablet before breakfastOral route1983-01-15 to 1984-08-18completedS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1981-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1982-03-01activeS
Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counterOne capsule at bedtimeOral route1983-10-01 to 1984-07-07stoppedS
Donepezil 5 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route1984-08-18 to 1984-09-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1984-08-18Body height180cmS
1984-08-18Body weight76.6kgS
1984-08-18Body mass index (BMI) [Ratio]23.6kg/m2S
1984-08-18Systolic blood pressure126mm[Hg]S
1984-08-18Diastolic blood pressure78mm[Hg]S
1984-08-18Heart rate70/minS
1984-08-18Respiratory rate14/minS
1984-08-18Body temperature36.6CelS
1984-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1984-08-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/78; pulse 70; weight 76.6 kg
Mental statusAttentive during the disclosure; asks good questions; mood sad but reactive
GaitSteady; Timed Up and Go 9 seconds

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be foundresolvedconfirmed R41.3S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, consideredactiveconfirmed G30.0S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease.
Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptomsactiveconfirmed F02.A0S — Synthetic stage at diagnosis.
Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylureaactiveconfirmed E11.9S — Synthetic modern diabetes anchored to his documented diabetes.
Hypertension, controlled on lisinoprilactiveconfirmed I10S — Synthetic modern hypertension anchored to the single press report.
Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometryactiveconfirmed H90.3S — Synthetic finding checked as a modifiable contributor to cognitive difficulty.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCognitive testing (MoCA, MMSE)At diagnosis, then yearly, or sooner with changeUp to dateMoCA 18 and MMSE 22 at diagnosis; next in a year
SurveyDementia staging (CDR) and function (ADL and IADL)At diagnosis, then yearlyUp to dateCDR 1 two weeks ago
ImagingAmyloid biomarker confirmation (PET or CSF)Once, when it will change diagnosis or treatmentCompleted todayAmyloid PET positive (about 90 Centiloids), reviewed with him today
Medication safetyAnti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI scheduleAt diagnosis of MCI or mild dementia due to Alzheimer's diseaseNot indicatedNot a candidate because of six microbleeds; explained to him today
Medication safetyMedicine review for anticholinergic and sedating drugs (Beers)Every visitCompleted todayNo anticholinergic or sedating drugs; glipizide stopped for hypoglycemia risk
SurveyBehavioral and psychological symptoms (NPI-Q items)Every visitCompleted todayNone; sad at the news without depression
Medication safetyCholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulseEach follow-up and each dose changeCompleted todayDonepezil 5 mg started after a normal ECG (pulse 70)
Self-managementDriving, firearm and home safetyAt diagnosis and each follow-upCompleted todayAgreed to stop driving; handgun to be removed from the home; stove shut-off advised
Self-managementCare partner support and burden (Zarit, narrative)At diagnosis, then at least yearlyCompleted todayZarit 18 (mild burden); helpline, caregiver class and adult day program arranged; GUIDE explained for when he has Medicare
Self-managementAdvance care planningAt diagnosis; revisit yearly and at changesDueBooked at the preventive visit in three weeks, while he can take part fully
LaboratoryHemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia reviewEvery three months after a therapy change; every six months when stableUp to date6.4% at intake; one low reading; glipizide stopped; A1c due in about three months
ExaminationBlood pressure, goal under 130/80 mmHgEvery visitCompleted today126/78 mmHg
LaboratoryPotassium and creatinine on lisinopril and metforminYearly, and after acute illness or dehydrationUp to dateNormal at intake
ExaminationDilated diabetic eye examinationEvery one to two years without retinopathyReferredStill pending; he now depends on others for transport
Self-managementExercise and social activityEvery visitCompleted todayWalks daily; the foundation gym twice a week

Goal progress:

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); Practice Parameter update: Evaluation and management of driving risk in dementia (2010); Guiding an Improved Dementia Experience (GUIDE) Model (2024)

Follow-up: Preventive visit with advance care planning in three weeks. Hearing aid fitting in two weeks. Eleven-week review with hemoglobin A1c. Call for low glucose readings, falls, or nausea on donepezil. Next scheduled visit 1984-09-08: periodic adult preventive visit. [S]